United States imposes 100% tariff on branded pharmaceutical imports
Change
United States will impose a 100% tariff on patented branded pharmaceuticals not made in the United States unless manufacturers sign most‑favored‑nation pricing pacts with the U.S. Department of Health and Human Services (HHS) or commit to U.S. production, with large companies required to announce plans within 120 days and smaller companies within 180 days.
Why it matters
Generics are excluded and the administration has already finalized deals that exempt 13 drugmakers so far, with a total of 17 firms in various stages of agreements that carry tariff relief for three years. Tariffs are cut to 15% for drugs produced in the European Union, Japan, South Korea and Switzerland under existing trade deals, while firms that relocate production to the United States can qualify for a reduced 20% tariff; the United Kingdom has a separate arrangement.
Implications
- • Government affairs teams at large branded pharmaceutical companies must announce within 120 days whether they will sign a pricing pact with the U.S. Department of Health and Human Services or commit to U.S. production — failure to announce will leave their patented imports subject to a 100% import duty.
- • Government affairs teams at small and mid‑sized branded pharmaceutical companies must announce within 180 days whether they will sign a pricing pact or commit to U.S. production — failure to announce will leave their patented imports subject to a 100% import duty.
Unlock the decision layer.
Go beyond headlines — see impact, exposure, and timing.
- Implications: What actually changes downstream.
- Who is affected: Which teams or operators are exposed.
- What to watch: Deadlines, triggers, and next moves.
- Real-time alerts: Know the moment a change is published.
- Ask AI: Clarify any brief instantly, in context.
14-day free trial. Full access. No credit card required.
Start free trial
Source
Topics